Clinical Evaluation
Symptoms or an imaging finding may lead to pelvic examination, ultrasound, CT or MRI, and blood tests such as CA-125.
Ovarian Cancer Pathology Support
Understanding Your Ovarian Cancer Pathology Report
Get a clearer explanation of the diagnosis, primary site, histologic type, grade when applicable, ovarian or fallopian-tube surface involvement, peritoneal or omental disease, treatment response, lymph nodes, and biomarker results documented in your pathology report.
This educational consultation explains your existing written pathology report. It does not provide a new diagnosis, written report, official document, treatment plan, or replacement for your treating clinicians.
Understand what your report documentsAnd what may still depend on surgery, imaging, biomarker testing, genetics, or other clinical information.
Board-Certified PathologistProfessional pathology-report guidance
Secure Virtual AppointmentMeet online from the comfort of home
Patient-Friendly ExplanationClear language for complex report findings
Educational SupportNot a replacement for medical advice
Understanding the Process
How an Ovarian Cancer Diagnosis Is Established
Imaging and blood tests can raise concern, but a tissue or cytology specimen is generally needed to identify the tumor type. The final pathology information depends on whether the specimen is a biopsy, fluid sample, ovary or tube removal, or a larger staging or debulking procedure.
Tissue or Fluid Sampling
A biopsy, surgery, peritoneal washing, ascitic fluid, or pleural fluid may provide cells or tissue for microscopic examination.
Pathology Diagnosis
The report identifies the tumor family and may use morphology, immunohistochemistry, and molecular studies to classify it.
Staging or Debulking Pathology
If surgery is performed, additional specimens may document the primary site, surface involvement, peritoneal disease, lymph nodes, and treatment effect.
“Ovarian cancer” includes different tumor families. Epithelial carcinomas, borderline tumors, germ-cell tumors, sex-cord stromal tumors, and tumors metastatic to the ovary are not interchangeable and may follow different reporting frameworks.
Different Reports, Different Questions
Biopsy or Cytology Versus Surgical Pathology
A biopsy or fluid specimen may establish that a malignancy is present and help classify it. A larger surgical specimen can provide additional information about the tumor’s origin, distribution, and pathologic extent.
Limited Diagnostic Sample
Biopsy or Cytology Report
A small tissue sample or fluid specimen may answer focused diagnostic questions but may not show the full anatomic picture.
- Whether malignant cells or tumor tissue are identified
- Most likely tumor family or histologic type
- Immunohistochemistry supporting classification or origin
- Whether the sample is adequate for additional testing
- Limitations caused by scant cells, necrosis, or sampling
Larger Surgical Specimen
Resection, Staging, or Debulking Report
Removal of an ovary or tube and other submitted tissues may document a broader set of required findings.
- Primary site, histologic type, and grade when applicable
- Tumor size and specimen integrity
- Ovarian or fallopian-tube surface involvement
- Omentum, peritoneum, and other tissue involvement
- Regional lymph nodes, pathologic categories, and treatment effect
Inside the Report
What Your Ovarian Pathology Report May Tell You
The available information depends on the tumor family, procedure, submitted tissues, and whether treatment occurred before surgery. A biopsy, fluid cytology, oophorectomy, salpingo-oophorectomy, and debulking report do not contain the same findings.
The primary site may be ovary, fallopian tube, tubo-ovarian, or peritoneum.
For high-grade serous carcinoma, careful examination of the fallopian tubes and the distribution of disease may influence how the site of origin is assigned.
Diagnosis and Primary Site
The report identifies the diagnosis and may assign the primary site as ovary, fallopian tube, tubo-ovarian, primary peritoneum, or another origin.
Histologic Type
Types include high-grade serous, low-grade serous, endometrioid, clear cell, mucinous, and other epithelial or non-epithelial tumors.
Grade When Applicable
Grading depends on tumor type. Some diagnoses incorporate grade into the name, while endometrioid, mucinous, and certain non-epithelial tumors use specific grading systems.
Tumor Size and Integrity
The report may document tumor dimensions and whether an ovarian capsule or fallopian-tube serosa was intact, ruptured, or fragmented.
Surface Involvement
Ovarian or fallopian-tube surface involvement is recorded separately from tumor confined within the organ.
Other Tissues and Organs
The report may document involvement of the opposite adnexa, uterus, pelvic or abdominal peritoneum, omentum, or other submitted sites.
Peritoneal Focus and Fluid
When applicable, the largest extrapelvic peritoneal focus is measured and peritoneal washings or ascitic fluid are reported.
Regional Lymph Nodes
When nodes are submitted, the report records whether tumor is present and may document the number and size of nodal metastases.
Need Help Understanding These Findings?
Review the terminology, primary-site assignment, specimen limitations, distribution of disease, and pending results in your existing ovarian pathology report during a secure virtual consultation.
pT1Limited to one or both ovaries or fallopian tubes
pT2Pelvic extension below the pelvic brim
pT3Peritoneal disease outside the pelvis
pNRegional lymph-node findings
Complete StageRequires wider pathologic and clinical information
Understanding Tumor Extent
How Anatomic Findings Relate to Pathologic Categories
For ovarian, fallopian-tube, and primary peritoneal carcinoma, pathologic categories reflect where tumor is found, including pelvic and extrapelvic peritoneal sites and regional lymph nodes. Complete stage is broader than any single line in the report.
Capsule, Surface, and Fluid Matter in pT1
Within pT1, laterality, capsule or serosal integrity, surface tumor, surgical spill, and malignant cells in ascites or peritoneal washings can affect the subcategory.
Extrapelvic Peritoneal Disease Is Size-Based
pT3 subcategories distinguish microscopic disease from macroscopic deposits and use the size of the largest extrapelvic peritoneal focus.
Stage Is Broader Than pT
Complete staging may also use regional nodes, distant-disease assessment, imaging, operative findings, cytology, and evaluation by the treating team.
Additional Pathology Findings
Features Considered With the Wider Clinical Picture
Additional findings may clarify the tumor’s origin, distribution, or response to prior therapy. Their meaning depends on the diagnosis, procedure, and full set of pathology and clinical records.
Specimen Integrity
The report may distinguish an intact capsule or serosa from preoperative rupture, intraoperative rupture, fragmentation, or an unknown time of rupture.
Fallopian-Tube Findings
Serous tubal intraepithelial carcinoma, tubal mucosal carcinoma, or an inseparable tubo-ovarian mass may contribute to primary-site assignment in high-grade serous carcinoma.
Peritoneum and Omentum
Reports may identify pelvic or abdominal peritoneal involvement, omental disease, and the size of the largest extrapelvic peritoneal focus.
Treatment Response
After presurgical therapy for high-grade serous carcinoma, a three-tier chemotherapy response score may be assessed in the omentum.
Primary Tumor or Metastasis to the Ovary
Some tumors from the gastrointestinal tract, pancreas, endometrium, cervix, or other sites can involve the ovary. Morphology, distribution, immunohistochemistry, and clinical information help pathologists evaluate origin.
Biomarker and Genetic Results
BRCA, HRD, MMR, and Other Selected Studies
Additional studies depend on the histologic type and clinical setting. Results may appear in the main pathology report, an addendum, a separate molecular report, or a genetics document.
Diagnostic Immunohistochemistry
Markers such as PAX8, WT1, p53, and others may help classify a tumor or evaluate its likely site of origin. The panel varies by case.
IHCp53
BRCA and HRD Testing
Tumor BRCA1/BRCA2 and homologous recombination deficiency testing may be performed, especially in high-grade serous carcinoma, and may be reported separately.
BRCA1/2HRD
MMR and Selected Biomarkers
Mismatch-repair testing is relevant for certain histologic types. Other biomarkers may be ordered according to the diagnosis and clinical context.
MMRSelected Tests
Tumor testing and inherited genetic testing are not the same. A tumor result may lead to or accompany germline testing through a genetics pathway. A consultation explains documented results without predicting treatment response or recommending therapy.
Questions About BRCA, HRD, MMR, or an Addendum?
Get a patient-friendly explanation of studies already documented in your reports and identify which results may still be pending or reported separately.
Putting the Results Together
What Is Confirmed, Pending, or Dependent on Other Information?
An ovarian pathology report may answer many important questions, but it may not provide the complete clinical picture on its own.
Confirmed in the Report
Documented Pathology Findings
The diagnosis, primary site, histologic type, grade when applicable, specimen integrity, surface involvement, submitted sites, treatment response, and nodes may be documented when the specimen allows.
May Still Be Pending
Addenda or Separate Results
Immunohistochemistry, BRCA, HRD, MMR, other biomarkers, outside consultation, later surgical specimens, or germline testing may still be pending or separately reported.
Requires Wider Context
Complete Stage and Treatment Planning
Complete staging and treatment decisions may also require imaging, operative findings, distant-disease assessment, health history, and evaluation by the treating care team.
How HONEST Pathology Helps
A Clearer Explanation of the Report You Already Have
A pathology report consultation helps you understand terminology and findings already documented, so you can approach conversations with your treating team with greater context and more focused questions.
Upload Your Report and Records
Submit the pathology report and relevant records requested for the consultation.
Meet Online With a Pathologist
Discuss the report during a private virtual appointment and ask questions about the documented findings.
Receive a Plain-Language Explanation
Better understand the terminology and prepare questions to discuss with your treating care team.
Consultation Scope
What the Consultation Includes and Excludes
A report explanation and a formal microscopic second opinion are different services. Clear boundaries help you choose the appropriate option.
The Consultation May Explain
- The documented diagnosis and ovarian pathology terminology
- Differences between biopsy, cytology, resection, staging, and debulking reports
- Primary site and histologic type
- Grade, tumor size, specimen integrity, and surface involvement when applicable
- Peritoneal or omental disease, fluid cytology, regional nodes, and treatment response
- Biomarker studies, specimen limitations, and pending results
- Questions to discuss with your treating team
The Consultation Does Not Include
- A new pathology diagnosis or replacement interpretation
- A new written report or official document
- Complete staging from the pathology report alone
- Treatment prescribing or replacement of the medical care team
- Pelvic examination, imaging interpretation, or assessment of symptoms
- Microscopic slide review unless a separate pathology second-opinion service is ordered
Choosing the Right Service
Report Consultation or Formal Pathology Second Opinion?
The right option depends on whether you need help understanding written results or an independent review of pathology slides, tissue, or digital images.
Frequently Asked Questions
Questions About Ovarian Cancer Pathology Reports
These answers provide general educational information. Individual reports vary according to tumor family, specimen, procedure, prior treatment, biomarker testing, and wider clinical situation.
Are ovarian, fallopian-tube, and primary peritoneal cancer the same?
They are not identical primary sites, but epithelial carcinomas arising in these locations can share histologic features and are staged within a related framework. The report may explain how the primary site was assigned.
What is the difference between a biopsy and a surgical pathology report?
A biopsy may establish malignancy and suggest a tumor type from limited tissue. A surgical specimen may add the primary site, tumor size, specimen integrity, surface involvement, other tissue involvement, regional nodes, and pathologic categories.
Is ovarian cancer grade the same as stage?
No. Grade concerns microscopic tumor features and is reported according to histologic type. Stage describes anatomic extent and may incorporate findings from pathology, surgery, imaging, and other clinical information.
What does high-grade serous carcinoma mean?
High-grade serous carcinoma is a specific histologic type that commonly involves the ovary, fallopian tube, and peritoneum. The report may also address primary-site assignment, p53 staining, disease distribution, and other studies.
What do capsule rupture and surface involvement mean?
Capsule integrity records whether an ovarian tumor was removed intact or ruptured and, when known, when rupture occurred. Surface involvement means tumor is present on the outer surface. These findings can affect the pathologic subcategory.
What is a chemotherapy response score?
For high-grade serous carcinoma treated before surgery, the report may use a three-tier score based on residual tumor and treatment-related changes in the omentum. The score is not applicable to every ovarian tumor.
Are tumor BRCA and inherited BRCA testing the same?
No. Tumor testing evaluates changes in cancer tissue, while germline testing evaluates inherited variants, usually from blood or saliva. The results may appear in separate reports and may require genetics interpretation.
When is a formal pathology second opinion more appropriate?
A formal second opinion may be appropriate when findings are complex, uncertain, unexpected, or when independent examination of the original slides or tissue could provide additional value.
Clearer Answers Begin Here
Understand the Findings in Your Ovarian Pathology Report
Meet online with a pathologist who can explain the terminology, primary site, tumor type, extent findings, specimen limitations, biomarker studies, and questions raised by your existing report.
Educational support only. This service does not replace your treating physician, gynecologist, gynecologic oncologist, surgeon, radiologist, genetic counselor, or medical care team.
